These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37335322)

  • 21. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
    Diefenbach C; Kahl BS; McMillan A; Briones J; Banerjee L; Cordoba R; Miall F; Burke JM; Hirata J; Jiang Y; Paulson JN; Chang YM; Musick L; Abrisqueta P
    Lancet Haematol; 2021 Dec; 8(12):e891-e901. PubMed ID: 34826412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes of primary and secondary prophylaxis of chemotherapy-induced and febrile neutropenia in bendamustine plus rituximab regimens in patients with lymphoma and chronic lymphocytic leukemia: real-world, single-center experience.
    Moore L; Bartels T; Persky DO; Abraham I; Kumar A; McBride A
    Support Care Cancer; 2021 Aug; 29(8):4867-4874. PubMed ID: 33547525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain.
    Sabater E; López-Guillermo A; Rueda A; Salar A; Oyagüez I; Collar JM
    Appl Health Econ Health Policy; 2016 Aug; 14(4):465-477. PubMed ID: 27090915
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma.
    Younes A; Burke JM; Diefenbach C; Ferrari S; Khan C; Sharman JP; Tani M; Ujjani C; Vitolo U; Yuen S; Raval A; Shivhare M; Nielsen TG; Sellam G; Gilbertson M
    Blood Adv; 2022 Oct; 6(20):5659-5667. PubMed ID: 35359000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Higher incidence of thrombocytopenia during obinutuzumab plus bendamustine therapy for untreated follicular lymphoma: a retrospective analysis by the Okayama Hematology Study Group.
    Fujiwara Y; Urata T; Niiya D; Yano T; Nawa Y; Yoshida I; Imai T; Sunami K; Fujii S; Ennishi D; Maeda Y; Hiramatsu Y
    Int J Hematol; 2022 Jun; 115(6):811-815. PubMed ID: 35583725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL).
    Boccomini C; Ladetto M; Rigacci L; Puccini B; Rattotti S; Volpetti S; Ferrero S; Chiarenza A; Freilone R; Novo M; Corradini P; Nassi L; Rusconi C; Stelitano C; Bolis S; Marina Liberati A; Tucci A; Baldini L; Balzarotti M; Evangelista A; Ciccone G; Vitolo U
    Br J Haematol; 2021 Apr; 193(2):280-289. PubMed ID: 33476434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma : An Evidence Review Group Evaluation of the NICE Single Technology Appraisal.
    Thielen FW; Büyükkaramikli NC; Riemsma R; Fayter D; Armstrong N; Wei CY; Huertas Carrera V; Misso K; Worthy G; Kleijnen J; Corro Ramos I
    Pharmacoeconomics; 2019 Aug; 37(8):975-984. PubMed ID: 30547368
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bendamustine-120 plus rituximab therapy for relapsed or refractory follicular lymphoma: a multicenter phase II study.
    Sakai R; Ohmachi K; Sano F; Watanabe R; Takahashi H; Takasaki H; Tanaka M; Hattori Y; Kimura H; Takimoto M; Tachibana T; Tanaka E; Ishii Y; Ishiyama Y; Hagihara M; Miyazaki K; Yamamoto K; Tomita N; Ando K
    Ann Hematol; 2019 Sep; 98(9):2131-2138. PubMed ID: 31286196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis of treatment regimens with obinutuzumab plus chemotherapy in Japan for untreated follicular lymphoma patients.
    Ohno S; Shoji A; Hatake K; Oya N; Igarashi A
    J Med Econ; 2020 Oct; 23(10):1130-1141. PubMed ID: 32620061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Obinutuzumab in follicular lymphoma.
    Martinez-Calle N; Figueroa-Mora R; Villar-Fernandez S; Marcos-Jubilar M; Panizo C
    Drugs Today (Barc); 2016 Dec; 52(12):643-651. PubMed ID: 28276536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-Effectiveness of Obinutuzumab in Combination with Bendamustine Followed by Obinutuzumab Maintenance versus Bendamustine Alone in Treatment of Patients with Rituximab-Refractory Follicular Lymphoma in Norway.
    Haukaas FS; Ohna A; Krivasi T
    Appl Health Econ Health Policy; 2018 Aug; 16(4):569-577. PubMed ID: 29923173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Follicular lymphoma: first - line selection criteria of treatment].
    Nesterova ES; Kravchenko SK; Kovrigina AM; Gemdzhian EG; Plastinina LV; Babaeva FE; Obukhova TN; Magomedova AU; Gaponova TV; Kremenetskaya AM; Vorobyev AI
    Ter Arkh; 2019 Aug; 91(8):75-83. PubMed ID: 32598757
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Front-line management of non-Hodgkin lymphoma in Australia. Part 1: follicular lymphoma.
    Trotman J; Cheah CY; Marlton P; Opat S
    Intern Med J; 2019 Apr; 49(4):422-433. PubMed ID: 30230156
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multicenter, Open-Label, Phase II Study of Bendamustine and Rituximab Followed by 90-Yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe).
    Lansigan F; Costa CA; Zaki BI; Yen SP; Winer ES; Ryan H; Findley D; Metzler SR; Shaw L; Toaso B; MacKenzie TA; Chen Y; Beaven AW
    Clin Cancer Res; 2019 Oct; 25(20):6073-6079. PubMed ID: 31243122
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of CHOP versus bendamustine on bone mineral density in patients with indolent lymphoma enrolled in the GALLIUM study.
    Pedersen MA; Gormsen LC; Jakobsen LH; Eyre TA; Severinsen MT; Baech J; Dann EJ; Knapp A; Sahin D; Vestergaard P; El-Galaly TC; Jensen P
    Br J Haematol; 2024 Apr; 204(4):1271-1278. PubMed ID: 37957542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Consolidation with
    Miura K; Tsujimura H; Masaki Y; Iino M; Takizawa J; Maeda Y; Yamamoto K; Tamura S; Yoshida A; Yagi H; Yoshida I; Kitazume K; Masunari T; Choi I; Kakinoki Y; Suzuki R; Yoshino T; Nakamura S; Hatta Y; Yoshida T; Kanno M
    Hematol Oncol; 2021 Feb; 39(1):51-59. PubMed ID: 32978820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Late-onset complications with bendamustine versus CHOP or CVP based chemoimmunotherapy in indolent Non-Hodgkin's lymphoma.
    Baek GT; Mathis NJ; Perissinotti AJ; Marini BL; Brown A; Phillips TJ; Wilcox RA; Nachar VR
    Leuk Lymphoma; 2021 Dec; 62(13):3138-3146. PubMed ID: 34263702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of obinutuzumab for the first-line treatment of follicular lymphoma: a subgroup analysis of Chinese patients enrolled in the phase III GALLIUM study.
    Hong X; Song Y; Shi Y; Zhang Q; Guo W; Wu G; Li J; Feng J; Kinkolykh A; Knapp A; Lin T
    Chin Med J (Engl); 2021 Sep; 135(4):433-440. PubMed ID: 35194005
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma.
    Zinzani PL; Mayer J; Flowers CR; Bijou F; De Oliveira AC; Song Y; Zhang Q; Merli M; Bouabdallah K; Ganly P; Zhang H; Johnson R; Martín García-Sancho A; Provencio Pulla M; Trněný M; Yuen S; Tilly H; Kingsley E; Tumyan G; Assouline SE; Auer R; Ivanova E; Kim P; Huang S; Delarue R; Trotman J
    J Clin Oncol; 2023 Nov; 41(33):5107-5117. PubMed ID: 37506346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.